Pasithea Therapeutics (KTTA) Gross Margin (2022)
Pasithea Therapeutics (KTTA) posted Gross Margin of 100.54% for Q4 2022, up 66.33% sequentially from 60.45% in Q3 2022.
Pasithea Therapeutics (KTTA) Gross Margin (2022) Analysis & Trends
Pasithea Therapeutics has reported Gross Margin for 1 years, with the latest figure at 100.54% in Q4 2022.
- Quarterly Gross Margin changed N/A year-over-year to 100.54% in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 76.74% (changed N/A YoY) and the FY2022 annual result came in at 76.74%, up 9143.0% from the prior year.
- Gross Margin improved to 100.54% in Q4 2022 per KTTA's latest filing, from 60.45% in the prior quarter.
- Over five years, Gross Margin peaked at 100.54% in Q4 2022 and troughed at 11.19% in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 76.90% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 84.20% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 63.27% |
| 10 | Pasithea Therapeutics | 15.13 Mn | 15.13 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 100.54% |
| Sep 30, 2022 | 60.45% |
| Jun 30, 2022 | -11.19% |
| Mar 31, 2022 | 5.28% |